Drug intelligence / Profile preview

NAL3923

Development stage: Preclinical
Lead developer: Nal Pharmaceuticals
Modality: Peptides
Administration: Oral

Overview

NAL3923 is an oral formulation of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, being developed by NAL Pharmaceutical Group for the treatment of obesity and weight loss. Utilizing NAL's proprietary oral delivery technology, NAL3923 is designed as a once-daily tablet to improve patient compliance and bioavailability compared to existing injectable or oral GLP-1 therapies. The drug acts by mimicking the incretin hormone GLP-1, which stimulates insulin secretion, inhibits glucagon release, and slows gastric emptying, thereby promoting satiety and weight reduction. It is currently in the preclinical stage of development.

Other names: Semaglutide 1-Day TabletSemaglutide1-Day TabletSemaglutide-1-Day Tablet

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on NAL3923.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NAL3923.

Explore the full profile